Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Kisspeptin and GPR54 may be the future of ovarian cancer treatment

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma, and are specific for the clear cell carcinoma subtype, research published this week in the online open access journal, BMC Medicine, reveals.

16 Nov 2007

Cultural habits influence oral cancers

Clinicians from the USC School of Dentistry unravel connection between the incidence of oral cancer and race and ethnicity-- as part of first epidemiological study of oral cancer in California.

15 Nov 2007

GPRC5A gene found to be a tumor-suppressor for lung cancer

The GPRC5A gene, which is under-expressed in human lung cancer cells, suppresses lung tumors in mouse models and could provide a key to attacking lung cancer in humans, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 21 edition of The Journal of the National Cancer Institute.

14 Nov 2007

Tumor-suppressor gene for lung cancer identified

14 Nov 2007

Cell response to stress signals predicts tumors in women with common pre-breast cancer

A specific biological response to cellular stress may predict the likelihood of future tumor formation of the most common, non-invasive form of pre-malignant breast cancer-- ductal carcinoma in situ, or DCIS.

13 Nov 2007

Molecular markers predict risk for invasive breast cancer years before the tumor develops

A team of scientists from the University of California San Francisco has identified distinct molecular markers that predict whether or not a woman is likely to develop subsequent invasive cancer after initial diagnosis with a noninvasive form of early breast cancer.

13 Nov 2007

First systemic therapy for fatal childhood disease - recessive dystrophic epidermolysis bullosa

University of Minnesota Children's Hospital, Fairview physicians have performed the first bone marrow and cord blood transplant to treat recessive dystrophic epidermolysis bullosa (RDEB).

5 Nov 2007

Does neural cell adhesion molecule-180 predict survival in colorectal cancer?

When a person learns they are suffering from cancer, the first question in their mind is always: "How much time do I have?" Unfortunately, this is a question to which the researchers have long been seeking an absolute answer.

5 Nov 2007

New model of esophageal cancer

In the November 1st issue of G&D, a team of scientists led by Dr. Anil Rustgi (UPENN) presents an innovative new model of esophageal cancer, which holds great promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease.

1 Nov 2007

How tumors respond to EGFR inhibitors

Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.

31 Oct 2007

Women still face cancer risk 25 years after treatment

Women are still at risk of developing invasive cancer of the cervix or vagina 25 years after being treated for pre-cancerous lesions, according to a study published today on bmj.com.

25 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

New target for Hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation.

25 Oct 2007

Cellular power plant fault explains abnormal metabolism of tumours

The increased consumption of glucose that tumour cells exhibit, was thought to be a cause of the extra demand of building blocks required to keep up with an uncontrolled cell growth, but now it is more accepted that it could be the effect of a programmed metabolic change that favours this malignant growth.

23 Oct 2007

Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma

Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC).

18 Oct 2007

Is the spleen able to prohibit tumor cell proliferation?

Primary and metastatic tumors of the spleen are described as unusual, excluding involvement by lymphoma.

17 Oct 2007

Delisheng shows anti-cancer effects on hepatocellular carcinoma

Traditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but the reason is still unknown. One such article was recently reported in the November 7 issue of the World Journal of Gastroenterology dealing with the great significance of a Chinese medicinal compound, "delisheng", for the therapy of HCC and its neoteric research method.

16 Oct 2007

Can liver cirrhosis be partially cured?

The diffusion of hepatitis C virus infection worldwide is astonishing. Liver cirrhosis is present in at least 10-20% of these infected patients, with highly increasing health care and emotional costs.

10 Oct 2007